Business
TherapeuticsMD Announces First Quarter 2022 Financial Results
- Quarterly total net product revenue of $19.3 million - - ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":"\n- Quarterly total net product revenue of $19.3 million -\n- ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 -\n- Announced and completed vitaCare divestiture in five weeks -\n- Conference call scheduled for 4:30 p.m. ET today -\n\n BOCA RATON, Fla.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the first quarter ended March 31, 2022.\n\n“Our revenue performance during the quarter was impacted by ANNOVERA manufacturing challenges as anticipated, but we believe these obstacles peaked in the first quarter of 2022 and expect incremental improvement as the year progresses. I’m also pleased to report that the $150 million divestiture of vitaCare that we announced during the quarter was driven to a successful conclusion, closing just five weeks following the announcement,” said Hugh O’Dowd, CEO of TherapeuticsMD.\n\n“With our increased focus and optimized sales organization, we believe that we will now be able to properly leverage all three of our assets and are confident these products can play a significant role in the marketplace,” concluded O’Dowd.\n\nFirst Quarter 2022 Financial Results and Business Highlights\n\n\n\n \n\n\n\n \n\n\n\nThree Months Ended March 31,\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n\n\nProduct revenue:\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nANNOVERA\n\n\n\n \n\n\n\n$\n\n\n\n8,510\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n8,750\n\n\n\n \n\n\n\n\n\nIMVEXXY\n\n\n\n \n\n\n\n \n\n\n\n6,969\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n7,012\n\n\n\n \n\n\n\n\n\nBIJUVA\n\n\n\n \n\n\n\n \n\n\n\n2,560\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n2,445\n\n\n\n \n\n\n\n\n\nPrescription vitamin\n\n\n\n \n\n\n\n \n\n\n\n875\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n1,425\n\n\n\n \n\n\n\n\n\nProduct revenue, net\n\n\n\n \n\n\n\n \n\n\n\n18,914\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n19,632\n\n\n\n \n\n\n\n\n\nLicense and service revenue\n\n\n\n \n\n\n\n \n\n\n\n419\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n234\n\n\n\n \n\n\n\n\n\nTotal revenue, net\n\n\n\n \n\n\n\n$\n\n\n\n19,333\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n19,866\n\n\n\n \n\n\n\n\nANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)\n\n\nANNOVERA net product revenue of $8.5 million...